RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase™

MARLBOROUGH, Mass., Jan. 5, 2015 /TRENDINGGLOBALNEWS/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7^th Annual Biotech Showcase™ 2015 on Monday, January 12, 2015 at 9:30 a.m. PST.  Dr. Cauwenbergh will provide an update on the Company's Dermatology and Ophthalmology Franchises. He will also discuss business development opportunities with RXi's broad delivery technology platform as well as the Company's robust intellectual property portfolio.

The presentation will be webcast and available on the "Investors" section of the Company's website, www.rxipharma.com. 

To schedule a meeting with RXi Pharmaceuticals' management team at this conference, contact Investor Relations at ir@rxipharma.com.            

About the Biotech Showcase

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,700 attendees.  This conference will take place January 12-14, 2015 at the Parc 55 Wyndham San Francisco Union Square Hotel, California.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, a self-delivering RNAi compound (sd-rxRNA), entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce the formation of dermal fibrosis (e.g., hypertrophic scars and keloids).  RXI-109 is designed to reduce the expression of connective tissue growth factor (CTGF), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin.  RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity. For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products, technologies and partnerships. Forward-looking statements about expectations and development plans of RXi's products and partnerships involve significant risks and uncertainties such as: the risk that we may not be able to successfully develop our candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based products; risks that the development process for our product candidates may be delayed, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties, the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this communication.

 source: http://www.prnewswire.com

Biotechnology Stocks Trader's Buzzers : Achillion Pharmaceuticals, (ACHN), Advaxis, Inc. (ADXS) , Alexion Pharmaceuticals, (ALXN) , Amgen, (AMGN) , Albany Molecular Research, (AMRI)

Biotechnology is the use of biological processes, organisms, or systems to manufacture products intended to improve the quality of human life. The earliest biotechnologists were farmers who developed improved species of plants and animals by cross pollenization or cross breeding. In recent years, biotechnology has expanded in sophistication, scope, and applicability.

The science of biotechnology can be broken down into subdisciplines called red, white, green, and blue. Red biotechnology involves medical processes such as getting organisms to produce new drugs, or using stem cells to regenerate damaged human tissues and perhaps re-grow entire organs. White (also called gray) biotechnology involves industrial processes such as the production of new chemicals or the development of new fuels for vehicles. Green biotechnology applies to agriculture and involves such processes as the development of pest-resistant grains or the accelerated evolution of disease-resistant animals. Blue biotechnology, rarely mentioned, encompasses processes in marine and aquatic environments, such as controlling the proliferation of noxious water-borne organisms. {1}

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed declined -0.33% to $12.25,recently declared positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422.

"We believe that achievement of 100 percent SVR4 in six weeks in the ACH-3102 proxy study, combined with the high potency and safety demonstrated by ACH-3422, highlights the ability of our exceptional, fully owned portfolio to excel in the HCV market," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We look forward to initiating in 2015 short duration, pan-genotypic Phase 2 therapeutic trials to evaluate the doublet of ACH-3102 and ACH-3422, with the ultimate goal of improving patient care and access to treatment."

Advaxis, Inc. (NASDAQ:ADXS) closed lower -8.87% to $8.01, a biotechnology organization developing cancer immunotherapies, declared that its Lm-LLO immunotherapy technology was highlighted on FOX News Channel's Sunday Housecall. The segment, which aired on December 28, 2014, featured Drs. Marc Siegel and David Samadi discussing Advaxis's cancer immunotherapy as a potential treatment for a range of cancer indications, including breast, prostate, osteosarcoma, and head and neck, due to its potential to trigger the immune system to directly attack cancer cells.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) closed gained 0.05% to $185.03, recently declared completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP). HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.1-5

Amgen, Inc. (NASDAQ:AMGN) closed declined -0.83% to $159.29, Amgen, Inc. and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, recently declared a contract in which Amgen has become a LabCentral platinum sponsor. As part of the sponsorship contract, Amgen can nominate up to two promising life-sciences and biotech startup companies per year to take up residence in LabCentral's Kendall Square facilities.

Albany Molecular Research, Inc. (NASDAQ:AMRI) closed increased 2.58% to $16.28, Levi & Korsinsky declares that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Albany Molecular Research Inc. (“Albany Molecular” or the “Company”) (AMRI) securities between August 5, 2014 and November 5, 2014.

 TAGs:

Achillion Pharmaceuticals, NASDAQ:ACHN, Advaxis, NASDAQ:ADXS , Alexion Pharmaceuticals, NASDAQ:ALXN , Amgen, NASDAQ:AMGN , Albany Molecular Research, NASDAQ:AMRI, ACHN, ADXS, ALXN, AMGN,AMRI

Source {1}: techtarget.com